KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Debt to Equity (2016)

Vertex Pharmaceuticals (VRTX) has 6 years of Debt to Equity data on record, last reported at $0.22 in Q4 2016.

  • For Q4 2016, Debt to Equity rose 9.52% year-over-year to $0.22; the TTM value through Dec 2016 reached $0.22, up 9.52%, while the annual FY2016 figure was $0.22, 9.52% up from the prior year.
  • Debt to Equity reached $0.22 in Q4 2016 per VRTX's latest filing, down from $0.25 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.3 in Q1 2015 and bottomed at $0.2 in Q4 2015.
  • Average Debt to Equity over 3 years is $0.26, with a median of $0.26 recorded in 2014.
  • Peak YoY movement for Debt to Equity: decreased 23.88% in 2015, then grew 9.52% in 2016.
  • A 3-year view of Debt to Equity shows it stood at $0.27 in 2014, then dropped by 23.88% to $0.2 in 2015, then increased by 9.52% to $0.22 in 2016.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $0.22 in Q4 2016, $0.25 in Q3 2016, and $0.25 in Q2 2016.